Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

The transaction between Thermo Fisher and Sanofi is scheduled for completion in Q2 2025, subject to standard closing ...

With an aim to enable additional U.S. drug product manufacturing, Thermo Fisher Scientific and Sanofi have decided to expand their strategic partnership. Under the terms of the agreement, Thermo ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.

Under the expanded partnership, Thermo Fisher will acquire Sanofi's sterile fill-finish and packaging facility in Ridgefield, N.J. The science-services and instruments provider said Wednesday that it ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).

The FDA on Wednesday granted accelerated approval to Regeneron ’s bispecific antibody linvoseltamab for the treatment of patients with relapsed or refractory multiple myeloma. The pharma will market ...